About Tesamorelin
A synthetic GHRH analogue approved by the FDA for HIV-associated lipodystrophy, studied for visceral fat reduction and metabolic effects.
Research dose ranges
- Dose: 1000–2000 mcg per administration
- Frequency: 1× per day
- Route: subcutaneous
- Half-life: ~0.43 hours
- Cycle: 26 weeks on / 8 off
The FDA-approved clinical dose is 2 mg (2000 mcg) subcutaneously once daily. Some research protocols use 1 mg daily. Rotate injection sites to minimize local reactions.
Storage
Store lyophilized vials at 2–8°C. Reconstituted solution should be refrigerated and used within 24 hours per manufacturer guidance; some research protocols extend this to 72 hours under strict cold-chain conditions.